Publications

Detailed Information

BubR1 as a prognostic marker for recurrence-free survival rates in epithelial ovarian cancers

Cited 31 time in Web of Science Cited 35 time in Scopus
Authors

Lee, Yoo-kyung; Choi, Eunhee; Kim, Min A; Park, Pil-gu; Park, Noh-hyun; Lee, Hyunsook

Issue Date
2009-08-04
Publisher
Nature Publishing Group
Citation
British Journal of Cancer 101: 504 – 510
Keywords
BubR1Aurora Aovarian neoplasmprognosisrecurrence-free survival
Abstract
BACKGROUND: Epithelial ovarian cancer is one of the most lethal malignancies, and has a high recurrence rate. Thus, prognostic markers
for recurrence are crucial for the care of ovarian cancer. As ovarian cancers frequently exhibit chromosome instability, we aimed at
assessing the prognostic significance of two key mitotic kinases, BubR1 and Aurora A.
METHODS: We analysed paraffin-embedded tissue sections from 160 ovarian cancer patients whose clinical outcomes had been
tracked after first-line treatment.
RESULTS: The median recurrence-free survival in patients with a positive and negative expression of BubR1 was 27 and 83 months,
respectively (Po0.001). A positive BubR1 expression was also associated with advanced stage, serous histology and high grade.
In contrast, Aurora A immunostaining did not correlate with any of the clinical parameters analysed.
CONCLUSION: BubR1, but not Aurora A, is a prognostic marker for recurrence-free survival rates in epithelial ovarian cancers.
ISSN
0007-0920
Language
English
URI
https://hdl.handle.net/10371/67628
DOI
https://doi.org/10.1038/sj.bjc.6605161
Files in This Item:
There are no files associated with this item.
Appears in Collections:

Altmetrics

Item View & Download Count

  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Share